Skip to main content
Top
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Rapid detection of SMARCB1 sequence variation using high resolution melting

Authors: Vinod Dagar, Chung-Wo Chow, David M Ashley, Elizabeth M Algar

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Rhabdoid tumors are rare cancers of early childhood arising in the kidney, central nervous system and other organs. The majority are caused by somatic inactivating mutations or deletions affecting the tumor suppressor locus SMARCB1 [OMIM 601607]. Germ-line SMARCB1 inactivation has been reported in association with rhabdoid tumor, epitheloid sarcoma and familial schwannomatosis, underscoring the importance of accurate mutation screening to ascertain recurrence and transmission risks. We describe a rapid and sensitive diagnostic screening method, using high resolution melting (HRM), for detecting sequence variations in SMARCB1.

Methods

Amplicons, encompassing the nine coding exons of SMARCB1, flanking splice site sequences and the 5' and 3' UTR, were screened by both HRM and direct DNA sequencing to establish the reliability of HRM as a primary mutation screening tool. Reaction conditions were optimized with commercially available HRM mixes.

Results

The false negative rate for detecting sequence variants by HRM in our sample series was zero. Nine amplicons out of a total of 140 (6.4%) showed variant melt profiles that were subsequently shown to be false positive. Overall nine distinct pathogenic SMARCB1 mutations were identified in a total of 19 possible rhabdoid tumors. Two tumors had two distinct mutations and two harbored SMARCB1 deletion. Other mutations were nonsense or frame-shifts. The detection sensitivity of the HRM screening method was influenced by both sequence context and specific nucleotide change and varied from 1: 4 to 1:1000 (variant to wild-type DNA). A novel method involving digital HRM, followed by re-sequencing, was used to confirm mutations in tumor specimens containing associated normal tissue.

Conclusions

This is the first report describing SMARCB1 mutation screening using HRM. HRM is a rapid, sensitive and inexpensive screening technology that is likely to be widely adopted in diagnostic laboratories to facilitate whole gene mutation screening.
Appendix
Available only for authorised users
Literature
1.
go back to reference Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B: Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer research. 1999, 59 (1): 74-79.PubMed Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B: Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer research. 1999, 59 (1): 74-79.PubMed
2.
go back to reference Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, Aurias A, Delattre O: Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998, 394 (6689): 203-206. 10.1038/28212.CrossRefPubMed Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, Aurias A, Delattre O: Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998, 394 (6689): 203-206. 10.1038/28212.CrossRefPubMed
3.
go back to reference Judkins AR, Burger PC, Hamilton RL, Kleinschmidt-DeMasters B, Perry A, Pomeroy SL, Rosenblum MK, Yachnis AT, Zhou H, Rorke LB, et al: INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. Journal of neuropathology and experimental neurology. 2005, 64 (5): 391-397.CrossRefPubMed Judkins AR, Burger PC, Hamilton RL, Kleinschmidt-DeMasters B, Perry A, Pomeroy SL, Rosenblum MK, Yachnis AT, Zhou H, Rorke LB, et al: INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. Journal of neuropathology and experimental neurology. 2005, 64 (5): 391-397.CrossRefPubMed
4.
go back to reference Xiangru Wu VD, Algar E, Muscat A, Bandopadhayay P, Ashley D, Chow CW: Rhabdoid tumour:a malignancy of early childhood with variable primary site, histology and clinical behaviour. Pathology. 2008, 40: 664-670. 10.1080/00313020802436451.CrossRefPubMed Xiangru Wu VD, Algar E, Muscat A, Bandopadhayay P, Ashley D, Chow CW: Rhabdoid tumour:a malignancy of early childhood with variable primary site, histology and clinical behaviour. Pathology. 2008, 40: 664-670. 10.1080/00313020802436451.CrossRefPubMed
5.
go back to reference Ammerlaan AC, Ararou A, Houben MP, Baas F, Tijssen CC, Teepen JL, Wesseling P, Hulsebos TJ: Long-term survival and transmission of INI1-mutation via nonpenetrant males in a family with rhabdoid tumour predisposition syndrome. British journal of cancer. 2008, 98 (2): 474-479. 10.1038/sj.bjc.6604156.CrossRefPubMed Ammerlaan AC, Ararou A, Houben MP, Baas F, Tijssen CC, Teepen JL, Wesseling P, Hulsebos TJ: Long-term survival and transmission of INI1-mutation via nonpenetrant males in a family with rhabdoid tumour predisposition syndrome. British journal of cancer. 2008, 98 (2): 474-479. 10.1038/sj.bjc.6604156.CrossRefPubMed
6.
go back to reference Biegel JA, Fogelgren B, Wainwright LM, Zhou JY, Bevan H, Rorke LB: Germline INI1 mutation in a patient with a central nervous system atypical teratoid tumor and renal rhabdoid tumor. Genes, chromosomes & cancer. 2000, 28 (1): 31-37. 10.1002/(SICI)1098-2264(200005)28:1<31::AID-GCC4>3.0.CO;2-Y.CrossRef Biegel JA, Fogelgren B, Wainwright LM, Zhou JY, Bevan H, Rorke LB: Germline INI1 mutation in a patient with a central nervous system atypical teratoid tumor and renal rhabdoid tumor. Genes, chromosomes & cancer. 2000, 28 (1): 31-37. 10.1002/(SICI)1098-2264(200005)28:1<31::AID-GCC4>3.0.CO;2-Y.CrossRef
7.
go back to reference Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P: Germline mutation of INI1/SMARCB1 in familial schwannomatosis. American journal of human genetics. 2007, 80 (4): 805-810. 10.1086/513207.CrossRefPubMedPubMedCentral Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P: Germline mutation of INI1/SMARCB1 in familial schwannomatosis. American journal of human genetics. 2007, 80 (4): 805-810. 10.1086/513207.CrossRefPubMedPubMedCentral
8.
go back to reference Modena P, Lualdi E, Facchinetti F, Galli L, Teixeira MR, Pilotti S, Sozzi G: SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer research. 2005, 65 (10): 4012-4019. 10.1158/0008-5472.CAN-04-3050.CrossRefPubMed Modena P, Lualdi E, Facchinetti F, Galli L, Teixeira MR, Pilotti S, Sozzi G: SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer research. 2005, 65 (10): 4012-4019. 10.1158/0008-5472.CAN-04-3050.CrossRefPubMed
9.
go back to reference Sevenet N, Sheridan E, Amram D, Schneider P, Handgretinger R, Delattre O: Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. American journal of human genetics. 1999, 65 (5): 1342-1348. 10.1086/302639.CrossRefPubMedPubMedCentral Sevenet N, Sheridan E, Amram D, Schneider P, Handgretinger R, Delattre O: Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. American journal of human genetics. 1999, 65 (5): 1342-1348. 10.1086/302639.CrossRefPubMedPubMedCentral
10.
go back to reference Taylor MD, Gokgoz N, Andrulis IL, Mainprize TG, Drake JM, Rutka JT: Familial posterior fossa brain tumors of infancy secondary to germline mutation of the hSNF5 gene. American journal of human genetics. 2000, 66 (4): 1403-1406. 10.1086/302833.CrossRefPubMedPubMedCentral Taylor MD, Gokgoz N, Andrulis IL, Mainprize TG, Drake JM, Rutka JT: Familial posterior fossa brain tumors of infancy secondary to germline mutation of the hSNF5 gene. American journal of human genetics. 2000, 66 (4): 1403-1406. 10.1086/302833.CrossRefPubMedPubMedCentral
11.
go back to reference Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ: High-resolution genotyping by amplicon melting analysis using LCGreen. Clinical chemistry. 2003, 49 (6 Pt 1): 853-860. 10.1373/49.6.853.CrossRefPubMed Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ: High-resolution genotyping by amplicon melting analysis using LCGreen. Clinical chemistry. 2003, 49 (6 Pt 1): 853-860. 10.1373/49.6.853.CrossRefPubMed
12.
go back to reference Fujisawa H, Takabatake Y, Fukusato T, Tachibana O, Tsuchiya Y, Yamashita J: Molecular analysis of the rhabdoid predisposition syndrome in a child: a novel germline hSNF5/INI1 mutation and absence of c-myc amplification. Journal of neuro-oncology. 2003, 63 (3): 257-262. 10.1023/A:1024345221792.CrossRefPubMed Fujisawa H, Takabatake Y, Fukusato T, Tachibana O, Tsuchiya Y, Yamashita J: Molecular analysis of the rhabdoid predisposition syndrome in a child: a novel germline hSNF5/INI1 mutation and absence of c-myc amplification. Journal of neuro-oncology. 2003, 63 (3): 257-262. 10.1023/A:1024345221792.CrossRefPubMed
13.
go back to reference Hadfield KD, Newman WG, Bowers NL, Wallace A, Bolger C, Colley A, McCann E, Trump D, Prescott T, Evans DG: Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. Journal of medical genetics. 2008, 45 (6): 332-339. 10.1136/jmg.2007.056499.CrossRefPubMed Hadfield KD, Newman WG, Bowers NL, Wallace A, Bolger C, Colley A, McCann E, Trump D, Prescott T, Evans DG: Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. Journal of medical genetics. 2008, 45 (6): 332-339. 10.1136/jmg.2007.056499.CrossRefPubMed
14.
go back to reference Janson K, Nedzi LA, David O, Schorin M, Walsh JW, Bhattacharjee M, Pridjian G, Tan L, Judkins AR, Biegel JA: Predisposition to atypical teratoid/rhabdoid tumor due to an inherited INI1 mutation. Pediatric blood & cancer. 2006, 47 (3): 279-284. 10.1002/pbc.20622.CrossRef Janson K, Nedzi LA, David O, Schorin M, Walsh JW, Bhattacharjee M, Pridjian G, Tan L, Judkins AR, Biegel JA: Predisposition to atypical teratoid/rhabdoid tumor due to an inherited INI1 mutation. Pediatric blood & cancer. 2006, 47 (3): 279-284. 10.1002/pbc.20622.CrossRef
Metadata
Title
Rapid detection of SMARCB1 sequence variation using high resolution melting
Authors
Vinod Dagar
Chung-Wo Chow
David M Ashley
Elizabeth M Algar
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-437

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine